Search Result

Results for "

Bivalent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (6) AUTACs (1) Autophagy (1) AUTOTACs (3) Bacterial (11) Bcl-2 Family (1) BCL6 (2) Biochemical Assay Reagents (12) c-Met/HGFR (3) Casein Kinase (4) CD3 (1) CD47 (1) CDK (2) E3 Ligase Ligand-Linker Conjugates (3) EGFR (2) Environmental Pollutants (4) Epigenetic Reader Domain (9) Ferroptosis (2) Hapten (4) Histamine Receptor (1) Histone Acetyltransferase (2) HIV (1) IAP (2) Interleukin Related (3) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Lactate Dehydrogenase (1) Melanocortin Receptor (1) Molecular Glues (2) mTOR (1) Opioid Receptor (1) PD-1/PD-L1 (2) PI3K (1) Prion Protein (1) PROTAC Linkers (2) PROTACs (1) PSMA (1) Pyruvate Kinase (1) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (4) SARS-CoV (2) SHP1 (1) SOD (11) Transthyretin (TTR) (1)
By Research Areas:	Cancer (55) Cardiovascular Disease (12) Endocrinology (1) Infection (3) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (12)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)
Oligonucleotides:	Antioxidants (1) Chelating Agents (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16591

Birinapant Maximum Cited Publications 42 Publications Verification TL32711	IAP Apoptosis HIV	Cancer
Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with K_ds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.

HY-Y0682

Ethylenediaminetetraacetic acid Maximum Cited Publications 29 Publications Verification EDTA	Environmental Pollutants Biochemical Assay Reagents Bacterial SOD	Cardiovascular Disease Neurological Disease Cancer
Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .

HY-111373

RapaLink-1 10+ Cited Publications	mTOR Autophagy	Cancer
RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .

HY-Y0682A

Ethylenediaminetetraacetic acid disodium dihydrate 20+ Cited Publications EDTA disodium dihydrate	Environmental Pollutants Biochemical Assay Reagents Bacterial SOD	Cardiovascular Disease Neurological Disease Cancer
Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research .

HY-P99391

Telisotuzumab ABT-700; ABBV-400 Antibody	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-100653

AZD5153 5 Publications Verification	Epigenetic Reader Domain Apoptosis	Cancer
AZD5153 is a bivalent, selective, and orally active BET/BRD4 bromodomain inhibitor with an IC₅₀ of value of 5 nM for full-length BRD4 (FL-BRD4). AZD5153 ligates two bromodomains in BRD4 simultaneously. AZD5153 can be used for the study of cancer, such as acute myeloid leukemia, multiple myeloma, and diffuse large B-cell lymphoma .

HY-P99192

Emibetuzumab LY2875358	c-Met/HGFR	Cancer
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .

HY-125593

Dasminapant APG-1387	IAP Apoptosis	Cancer
Dasminapant (APG-1387), a bivalent SMAC mimetic and an IAP antagonist, blocks the activity of IAPs family proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). Dasminapant induces degradation of cIAP-1 and XIAP proteins, as well as caspase-3 activation and PARP cleavage, which leads to apoptosis. Dasminapant can be used for the research of hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma .

HY-P99947

Rimteravimab XVR011	SARS-CoV	Infection
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .

HY-169244

CDK-TCIP1	CDK Bcl-2 Family	Cancer
CDK-TCIP1 is a bivalent molecule linking CDK9 inhibitor SNS-032 (HY-10008) to BCL6 ligand BI3812 (HY-111381). CDK-TCIP1 potently and specifically kills BCL6-overexpressing cells with EC₅₀ of 7.7 nM for SUDHL5 cells .

HY-P99728

Melredableukin alfa RG7835; RO7049665	Interleukin Related	Metabolic Disease Inflammation/Immunology
Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis .

HY-108350

MI-2-2 1 Publications Verification	Epigenetic Reader Domain	Cancer
MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K_d=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .

HY-B1009

Ethylenediaminetetraacetic acid trisodium salt 25+ Cited Publications EDTA trisodium salt; Trisodium EDTA	Environmental Pollutants Bacterial SOD Ferroptosis	Cardiovascular Disease Neurological Disease Cancer
Ethylenediaminetetraacetic acid trisodium salt (EDTA trisodium salt; Trisodium EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid trisodium salt has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid trisodium salt decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid trisodium salt can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .

HY-125232

MS645 1 Publications Verification	Epigenetic Reader Domain	Cancer
MS645 is a bivalent BET bromodomains (BrD) inhibitor with a K_i of 18.4 nM for BRD4-BD1/BD2. MS645 spatially constrains bivalent inhibition of BRD4 BrDs resulting in a sustained repression of BRD4 transcriptional activity in solid-tumor cells .

HY-111976

MT1	Epigenetic Reader Domain	Cancer
MT1 is a bivalent chemical probe of BET bromodomains, with an IC₅₀ of 0.789 nM for BRD4(1) .

HY-W127774

EDTA hydrate sodium 20+ Cited Publications Ethylenediaminetetraacetic acid hydrate sodium	Biochemical Assay Reagents Bacterial SOD	Cardiovascular Disease Neurological Disease Cancer
EDTA (Ethylenediaminetetraacetic acid) hydrate sodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA hydrate sodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA hydrate sodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA hydrate sodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .

HY-173552

TCIP3	Molecular Glues Histone Acetyltransferase BCL6	Cancer
TCIP3 is a bivalent molecular glue with with dual binding to p300/CBP and BCL6. TCIP3 redirects p300 and CBP to activate programmed cell death genes normally repressed by the oncogenic driver, BCL6. TCIP3 can be used for the study of diffuse large B cell lymphomas (DLBCLs). TCIP3 exhibits no toxicity in non-transformed tonsillar lymphocytes or fibroblasts .

HY-155218

TMX-2172	PROTACs CDK	Cancer
TMX-2172 is a selective bivalent cereblon-recruiting PROTAC-based dual CDK2 and CDK5 degrader with IC₅₀ values of 6.5 nM and 6.8 nM, respectively. TMX-2172 shows selectivity for CDK2 and CDK5 over other cell cycle CDKs (CDK1, CDK4, and CDK6) and transcriptional CDKs (CDK7 and CDK9). TMX-2172 inhibits CDK2/CDK5 enzymatic activity, induces their proteasomal degradation, reduces ASCL1 protein levels and half-life, induces cancer cell death, and exerts antiproliferative effects. TMX-2172 can be used for the research of ovarian cancer and small cell lung cancer .

HY-122702

PEG6-(CH2CO2H)2	PROTAC Linkers	Others
PEG6-(CH2CO2H)2 is a symmetric PEG PROTAC linker, for the synthesis of Homo-PROTACs which is bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation .

HY-P99903

Simridarlimab IBI-322	PD-1/PD-L1 CD47	Inflammation/Immunology Cancer
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .

HY-Y0682B

Ethylenediaminetetraacetic acid tetrasodium 20+ Cited Publications EDTA tetrasodium	Environmental Pollutants Biochemical Assay Reagents Bacterial SOD	Cardiovascular Disease Neurological Disease Cancer
Ethylenediaminetetraacetic acid (EDTA) tetrasodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid tetrasodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid tetrasodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid tetrasodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid tetrasodium can be used for coronary artery disease and neural system disease research .

HY-176508

KDX1381	Casein Kinase	Cancer
KDX1381 is a bivalent CK2α inhibitor (IC₅₀: 17 nM, K_D: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .

HY-162152

biKEAP1	Keap1-Nrf2	Inflammation/Immunology
biKEAP1 (compound 3) is an inhibitor targeting the dimerKEAP1. biKEAP1 binds to cellular KEAP1 dimers and releases the NRF2 protein sequestered by KEAP1, resulting in immediate activation of NRF2. biKEAP1 also promotes nuclear translocation of NRF2 and directly inhibits proinflammatory cytokine transcription. biKEAP1 can reduce acute inflammation and reduce inflammatory damage in acute inflammation models .

HY-W105700

Ethylenediaminetetraacetic acid sodium hydrate 20+ Cited Publications EDTA sodium hydrate	Biochemical Assay Reagents Bacterial SOD	Cardiovascular Disease Neurological Disease Cancer
Ethylenediaminetetraacetic acid (EDTA) sodium hydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid sodium hydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid sodium hydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid sodium hydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid sodium hydrate can be used for coronary artery disease and neural system disease research .

HY-W087947

EDTA dihydrate tripotassium 20+ Cited Publications Ethylenediaminetetraacetic acid dihydrate tripotassium	Bacterial SOD	Cardiovascular Disease Neurological Disease Cancer
EDTA dihydrate tripotassium (Ethylenediaminetetraacetic acid dihydrate tripotassium) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA dihydrate tripotassium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA dihydrate tripotassium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA dihydrate tripotassium can alleviate the liver fibrosis. EDTA dihydrate tripotassium can be used for coronary artery disease and neural system disease research .

HY-P991708

Olsutamig REGN-4336	PSMA CD3	Cancer
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .

HY-123626

BiBET	Epigenetic Reader Domain	Cancer
BiBET is a chemical probe of BET/BRD4 and is able to bind to two bromodomains simultaneously in a bivalent and cis-binding mode .

HY-178980

APL-5125	Casein Kinase	Cancer
APL-5125 (Compound 61f) is a potent, selective and orally active ATP-competitive CK2α inhibitor with an IC₅₀ of 0.348 nM and a K_i of 0.095 nM. APL-5125 binds to CK2α in a bivalent manner, simultaneously interacting with the ATP-binding site and the αD pocket. APL-5125 exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .

HY-178235

MDAN-21	Opioid Receptor	Neurological Disease
MDAN-21 is a bivalent opioid ligand that contains both μ-opioid receptor agonists and δ-opioid receptor antagonists. MDAN-21 has a strong analgesic effect and does not produce tolerance in mouse studies. MDAN-21 can effectively inhibit the withdrawal of morphine dependent monkeys and alleviate abnormal pain in the study of rhesus monkeys. MDAN-21 can be used for the study of allodynia .

HY-169387

YT 6-2-PEG3-C2-NH2	AUTOTACs	Cancer
YT 6-2-PEG3-C2-NH2 is the p62/SQSTM1 targeting, autophagy-targeting ligand-linker conjugate of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-169388

YT 6-2	AUTACs	Cancer
YT 6-2 is the p62/SQSTM1 targeting, autophagy-targeting ligand (ATL) of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .

HY-P991720

Tepilukimig	Interleukin Related	Inflammation/Immunology
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .

HY-174350

CK2-IN-15	Casein Kinase SARS-CoV	Infection
CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC₅₀ value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases .

HY-B1009R

Ethylenediaminetetraacetic acid trisodium salt (Standard) EDTA trisodium salt (Standard); Trisodium EDTA (Standard)	Ferroptosis Bacterial SOD Reference Standards	Cardiovascular Disease Neurological Disease Cancer
Ethylenediaminetetraacetic acid (trisodium salt) (Standard) is the analytical standard of Ethylenediaminetetraacetic acid (trisodium salt). This product is intended for research and analytical applications. Ethylenediaminetetraacetic acid trisodium salt (EDTA trisodium salt; Trisodium EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid trisodium salt has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid trisodium salt decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid trisodium salt can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .

HY-123853

CAM4066	Casein Kinase	Cancer
CAM4066 is a potent CK2α inhibitor, with an IC₅₀ value of 300 nM. CAM4066 exhibits high selectivity, with IC₅₀ values of 22.35, 43.55, and > 50 μM for HIPK3, DAPK3, and CLK2, respectively. CAM4066 shows no cell activity. CAM4066 can be used for the development of highly potent CK2 inhibitors .

HY-169385

ATC-324	AUTOTACs Androgen Receptor	Cancer
ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).

HY-155447

AG3.0	Hapten	Cancer
AG3.0 is a symmetric di-HSG bivalent hapten. AG3.0 can be used for the research of pretargeted radioimmunotherapy .

HY-162300

EGFR kinase inhibitor 4	EGFR	Cancer
EGFR kinase inhibitor 4 (Compound 4) is a bivalent ATP-allosteric EGFR inhibitor (IC₅₀: 1.8 nM for mutant EGFR (LRTMCS)). EGFR kinase inhibitor 4 can be used for research of NSCLC .

HY-162299

EGFR kinase inhibitor 3	EGFR	Cancer
EGFR kinase inhibitor 3 (compound 2) is a bivalent ATP-allosteric EGFR kinase inhibitor with IC₅₀s of <10 nM, 1.5 nM, 0.059 nM, 0.064 nM for WT EGFR, EGFR-activating mutations L858R, L858R/T790M and L858R/T790M/C797S, respectively. EGFR kinase inhibitor 3 is a C-linked inhibitor .

HY-155469

IMP 241	Hapten	Others
IMP 241 is a di-HSG bivalent hapten .

HY-155445

di-DTPA TL	Hapten	Cancer
di-DTPA TL is a hydrophilic bivalent DTPA hapten that can be used for tumor research .

HY-155444

AG5.0	Histamine Receptor	Cancer
AG5.0 is a bivalent hapten contains one HSG (histamine-succinyl-glycyl) group and one DTPA-indium group .

HY-155468

AG8.0	Biochemical Assay Reagents	Others
AG8.0 is a symmetric di-HSG bivalent hapten. AG8.0 is stable in vivo for 24 h .

HY-161473

Apoptosis inducer 16	Apoptosis	Cancer
Apoptosis inducer 16 (Compound 3) is a bivalent Smac mimic that can effectively bind to BIR2 and BIR3, and exhibits cancer cell (apoptosis) inducing activity .

HY-138865

BiCAPPA	Prion Protein	Infection
BiCAPPA is the first bivalent antiprion ligand. BiCAPPA can decrease infectious conformational form of prion protein (PrP ^Sc) from scrapie-infected cells, with an EC₅₀ of 0.32 μM .

HY-155471

IMP 245	Biochemical Assay Reagents	Others
IMP 245 is a symmetric di-HSG bivalent hapten. IMP 245 has low toxicity, high affinity binding to available antibodies and absence of cross reactivity or non-specific binding with body components .

HY-176233

Transthyretin-IN-4	Transthyretin (TTR)	Cardiovascular Disease
Transthyretin-IN-4 (Compound B26) is a bivalent inhibitor of transthyretin (TTR) amyloidosis (bIC₅₀: 0.09 µM, pIC₅₀: 1.4 µM). Transthyretin-IN-4 is used in the study of fatal heart failure with preserved ejection fraction (HFpEF) and fatal arrhythmias .

HY-155470

IMP 243	Biochemical Assay Reagents	Cancer
IMP 243 is a symmetric di-HSG (histamine-succinyl-glycine) bivalent hapten containing a Tscg-Cys ligand and two HSG groups. IMP 243 can be radiolabeled with ^99mTc-pertechnetate. IMP 243 can be conjugated to other peptides to design bispecific antibodies (bsMAbs) for cancer research .

HY-133189

Bis-propargyl-PEG9	PROTAC Linkers	Endocrinology
Bis-propargyl-PEG9 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands . Bis-propargyl-PEG9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Type

HY-Y0682

Ethylenediaminetetraacetic acid

Maximum Cited Publications

29 Publications Verification

EDTA

Biochemical Assay Reagents

Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .

HY-Y0682A

Ethylenediaminetetraacetic acid disodium dihydrate

20+ Cited Publications

EDTA disodium dihydrate

Biochemical Assay Reagents

Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research .

HY-W127774

EDTA hydrate sodium

20+ Cited Publications

Ethylenediaminetetraacetic acid hydrate sodium

Biochemical Assay Reagents

EDTA (Ethylenediaminetetraacetic acid) hydrate sodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA hydrate sodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA hydrate sodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA hydrate sodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .

HY-W105700

Ethylenediaminetetraacetic acid sodium hydrate

20+ Cited Publications

EDTA sodium hydrate

Biochemical Assay Reagents

Ethylenediaminetetraacetic acid (EDTA) sodium hydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid sodium hydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid sodium hydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid sodium hydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid sodium hydrate can be used for coronary artery disease and neural system disease research .

HY-W087947

EDTA dihydrate tripotassium

20+ Cited Publications

Ethylenediaminetetraacetic acid dihydrate tripotassium

Biochemical Assay Reagents

EDTA dihydrate tripotassium (Ethylenediaminetetraacetic acid dihydrate tripotassium) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA dihydrate tripotassium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA dihydrate tripotassium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA dihydrate tripotassium can alleviate the liver fibrosis. EDTA dihydrate tripotassium can be used for coronary artery disease and neural system disease research .

HY-Y0682R

Ethylenediaminetetraacetic acid (Standard)

EDTA (Standard)

Biochemical Assay Reagents

Ethylenediaminetetraacetic acid (Standard) is the analytical standard of Ethylenediaminetetraacetic acid. This product is intended for research and analytical applications. Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research [4] .

HY-Y0682AR

Ethylenediaminetetraacetic acid disodium dihydrate (Standard)

EDTA disodium dihydrate (Standard)

Biochemical Assay Reagents

Ethylenediaminetetraacetic acid (disodium dihydrate) (Standard) is the analytical standard of Ethylenediaminetetraacetic acid (disodium dihydrate). This product is intended for research and analytical applications. Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research [4] .

Cat. No.	Product Name	Target	Research Area

HY-P11280A

PRAME peptide (425-433) acetate	Melanocortin Receptor	Cancer
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99391

Telisotuzumab ABT-700; ABBV-400 Antibody	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P99192

Emibetuzumab LY2875358	c-Met/HGFR	Cancer
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .

HY-P99947

Rimteravimab XVR011	SARS-CoV	Infection
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .

HY-P99728

Melredableukin alfa RG7835; RO7049665	Interleukin Related	Metabolic Disease Inflammation/Immunology
Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis .

HY-P99903

Simridarlimab IBI-322	PD-1/PD-L1 CD47	Inflammation/Immunology Cancer
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .

HY-P991708

Olsutamig REGN-4336	PSMA CD3	Cancer
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P991720

Tepilukimig	Interleukin Related	Inflammation/Immunology
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .

HY-P992339

cT84.66	Radionuclide-Drug Conjugates (RDCs)	Cancer
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies .

HY-P992434

OSE-279	PD-1/PD-L1 SHP1 Interleukin Related	Cancer
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .

Cat. No.	Product Name	Chemical Structure

HY-W777365

Ethylenediaminetetraacetic acid-13C4

Ethylenediaminetetraacetic acid- ¹³C₄ (EDTA- ¹³C₄) is the ¹³C-labeled Ethylenediaminetetraacetic acid (HY-Y0682). Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .

Cat. No.	Product Name		Classification

HY-133189

Bis-propargyl-PEG9		Alkynes PROTAC Synthesis
Bis-propargyl-PEG9 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands . Bis-propargyl-PEG9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-Y0682A

Ethylenediaminetetraacetic acid disodium dihydrate 20+ Cited Publications EDTA disodium dihydrate		Antioxidants Chelating Agents
Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: